US6963891055 - Common Stock
Taking everything into account, PALI scores 2 out of 10 in our fundamental rating. PALI was compared to 254 industry peers in the Pharmaceuticals industry. PALI has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, PALI is valued expensive at the moment.
ROA (-58.2%) VS Industry: 36% outperformed.
Price/Book (0.46) VS Industry: 87% outperformed.
Enterprise Value/ EBITDA (0.49) VS Industry: 83% outperformed.
Debt/Equity (0) VS Industry: 54% outperformed.
Quick Ratio (4.31) VS Industry: 59% outperformed.
Current Ratio (4.31) VS Industry: 57% outperformed.
Altman-Z (-10.4) VS Industry: 12% outperformed.
NASDAQ:PALI (11/30/2022, 11:00:07 AM)-0.19 (-4.9%)
|GICS Sector||Health Care|
|GICS IndustryGroup||Pharmaceuticals, Biotechnology & Life Sciences|
|Earnings (Last)||11-14 2022-11-14/bmo||Earnings (Next)||03-16 2023-03-16|
|Ins Owners||14.36%||Inst Owners||545.06%|
|PEG (NY)||N/A||PEG (5Y)||N/A|
|Dividend Yield||N/A||Dividend Growth||N/A|
|EPS 1Y||87.04%||EPS 3Y||N/A|
|EPS 5Y||N/A||EPS growth Q2Q||-119.05%|
|EPS Next Y||87.5%||EPS Next 2Y||39.74%|
|EPS Next 3Y||25.21%||EPS Next 5Y||14.02%|
|Revenue growth 1Y||-100%||Revenue growth 3Y||N/A|
|Revenue growth 5Y||N/A||Revenue growth Q2Q||N/A|
|Revenue Next Year||N/A||Revenue Next 2Y||N/A|
|Revenue Next 3Y||N/A||Revenue Next 5Y||N/A|
|Current Ratio||4.31||Quick Ratio||4.31|
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA